A carregar...
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
Monoclonal antibodies can block cellular interactions that negatively regulate T-cell immune responses, such as CD80/CTLA-4 and PD-1/PD1-L, amplifying preexisting immunity and thereby evoking antitumor immune responses. Ibrutinib, an approved therapy for B-cell malignancies, is a covalent inhibitor...
Na minha lista:
| Publicado no: | Proc Natl Acad Sci U S A |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
National Academy of Sciences
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4352777/ https://ncbi.nlm.nih.gov/pubmed/25730880 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1500712112 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|